DadFinStart your free week
DadFin › Stocks › Healthcare › NBIX

Neurocrine Biosciences, Inc. (NBIX) stock score

Healthcare · Drug Manufacturers - Specialty & Generic · United States

$142.44 ▲ +0.84% today

98.4
Dad Score, out of 100
strong

Neurocrine Biosciences, Inc. (NBIX) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, listed in the United States. On DadFin's weekly run it scores 98.4 out of 100 on the Dad Score, a strong reading that places the business ahead of 98% of the 5,774 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #18 of 974. Its strongest axes are valuation, quality and growth; its weakest is risk.

Scores from the run of Oct 4, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Strong
Quality
Strong
Growth
Strong
Price action
no inputs
Risk
Below average
Conviction
Average
Liquidity
Strong
Macro
Above average

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)20.9×
P/E (forward)12.1×
Dividend yield0.00%
Return on capital18.1%
Operating margin22.2%
Revenue growth (YoY)+21.5%
FCF yield5.4%
Net debt / EBITDA0.08×
Piotroski F-Score5 / 9
52-week change+2.7%
Market cap$14.6B
Next earningsOct 28, 2026

What subscribers see on NBIX

Start your free weekSubscriber? Open the full research →

Drug Manufacturers - Specialty & Generic peers

StockCompanyDad ScoreBandMarket cap
TAKTakeda Pharmaceutical Company Limi32.9weak$57.1B
TEVATeva Pharmaceutical Industries Lim93.6strong$46.1B
HLNHaleon plc64.5middling$38.7B
ZTSZoetis Inc.61.2middling$28.8B
UTHRUnited Therapeutics Corporation99.8strong$23.2B
VTRSViatris Inc.54.4middling$20.2B
ELANElanco Animal Health Incorporated84.0good$11.1B
RDYDr. Reddy's Laboratories Limited28.5weak$10.2B

Prices from DadFin's live feed (refreshed about every 15 minutes in the session); scores from the weekly run of Oct 4, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.